SCHEDULE: Forager Capital Proposes $4.80/Share Buyout of Repay

Forager Capital Management has submitted a non-binding proposal to acquire all outstanding shares of Repay Holdings Corp for $4.80 per share in cash.

Summary

• Forager Capital Management, currently holding approximately 12.9% of Repay Holdings Corp, has proposed a cash acquisition of all remaining outstanding shares.
• The offer price of $4.80 per share represents a 75% premium over the 30-day volume-weighted average price of $2.75.
• The proposal is non-binding and contingent upon the execution of definitive documentation and confirmatory due diligence.
• Forager states the offer is not subject to a financing condition and they have sufficient capital to complete the transaction.
• The bidder expressed disappointment regarding the Board's recent implementation of a shareholder rights plan following initial exploratory outreach.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development for shareholders due to the significant premium offered, though the hostile nature of the bid and the Board's defensive posture introduce substantial uncertainty.

Positives

• The offer provides a significant 75% premium over the 30-day volume-weighted average price.
• The proposal offers immediate liquidity and cash certainty for shareholders.
• The bidder claims the offer is not subject to a financing condition, reducing execution risk.
• The bidder cites a recent successful acquisition of Quipt Home Medical as evidence of their ability to close transactions.

Negatives

• The proposal is non-binding and subject to due diligence and board approval.
• The Board of Directors has already implemented a shareholder rights plan (poison pill) in response to the bidder's initial outreach, signaling potential resistance.
• The bidder notes that the company's public market valuation may be suffering from short-term focus, which could lead to a valuation dispute.

Risks

• The Board may reject the proposal, leading to a potential proxy contest or termination of the offer.
• The shareholder rights plan could significantly complicate or block the acquisition attempt.
• Regulatory approvals are required, which could delay or prevent the transaction.
• The transaction is subject to the negotiation of a definitive merger agreement, which may not be reached.

Future Outlook

The bidder intends to conduct confirmatory due diligence simultaneously with the negotiation of a definitive merger agreement to move toward a swift closing.

Management Comments

• We believe this response (the shareholder rights plan) is difficult to reconcile with a genuine commitment to maximizing shareholder value.
• We believe the Company will be best equipped to execute its mission as a private entity, removing certain public company costs, responsibilities, obligations, and distractions.
• We are highly confident in our ability to bring this Transaction to a successful close on an accelerated timeframe.

Industry Context

StockSavvy.ai notes that this move reflects a broader trend of private equity and activist investors targeting small-cap fintech companies that are trading at depressed valuations relative to their perceived intrinsic value.

Comparison to Industry Standards

• The 75% premium is significantly higher than the typical 20-30% premiums seen in standard strategic M&A transactions.
• The use of a 'poison pill' (shareholder rights plan) by the target board is a standard defensive tactic in the small-cap sector to prevent unsolicited takeovers.
• The bidder's reference to the Quipt Home Medical acquisition suggests a strategy of taking undervalued public companies private, a common trend in the current high-interest-rate environment.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant short-term capital gains if the deal is accepted.
• Employees/Vendors: Potential for operational changes if the company is taken private.
• Board of Directors: Facing pressure to evaluate the offer against their fiduciary duties.

Next Steps

• Board of Directors review of the proposal.
• Potential negotiation of a confidentiality agreement.
• Commencement of confirmatory due diligence.
• Potential negotiation of a definitive merger agreement.

Key Dates

Recommendation

Investors should hold pending the Board's formal response; the 75% premium is attractive, but the implementation of a poison pill suggests a high probability of a protracted battle or rejection, which could lead to volatility.

Keywords

Repay Holdings, Forager Capital, Merger and Acquisition, Takeover Bid, Shareholder Value, Private Equity, Fintech